Status:

COMPLETED

A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

Lead Sponsor:

Embera NeuroTherapeutics, Inc.

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

Conditions:

Cocaine Use Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam...

Detailed Description

This study is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, study to compare the safety and efficacy of EMB-001 with a placebo control in approximately 80 subjects with mode...

Eligibility Criteria

Inclusion

  • Key
  • Provide written informed consent prior to any study procedures
  • 18 to 65 years of age
  • DSM-5 diagnosis of moderate-to-severe CUD
  • Seeking treatment for CUD. Subjects with past rehabilitation attempts are eligible if the most recent rehabilitation attempt ended at least 30 days prior to Screening
  • Female subjects must be of non-childbearing potential
  • Male subjects must agree to use accepted contraceptive regimens during the study and for at least 90 days after the last dose of the study drug
  • Key

Exclusion

  • Any significant current medical conditions
  • Known hypersensitivity to or intolerance of oxazepam, metyrapone, or any benzodiazepine, or severe hypersensitivity reaction (e.g., angioedema) to any drug
  • Heightened likelihood of having adrenal insufficiency in the investigator's or designees' opinion
  • Current court-mandated treatment requirement for a substance-use disorder
  • Current DSM-5 moderate-to-severe substance use disorder, other than CUD, tobacco or caffeine
  • Current DSM-5 opioid or benzodiazepine use disorder of any severity

Key Trial Info

Start Date :

July 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 15 2022

Estimated Enrollment :

82 Patients enrolled

Trial Details

Trial ID

NCT04501874

Start Date

July 29 2020

End Date

October 15 2022

Last Update

August 8 2023

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Pacific Treatment and Research Center, Department of Psychiatry, University of California, San Diego, School of Medicine

San Diego, California, United States, 92092

2

Segal Trials

Miami, Florida, United States, 33161

3

U PENN- Perelman School of Medicine

Philadelphia, Pennsylvania, United States, 19104

4

Medical University of South Carolina

Charleston, South Carolina, United States, 29403